Nivolumab and relatlimab-rmbw - Biologic Drug Details

Summary for nivolumab and relatlimab-rmbw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for nivolumab and relatlimab-rmbw

Mechanism of Action	Lymphocyte Activation Gene-3 Antagonists Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Lymphocyte Activation Gene-3 Blocker Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for nivolumab and relatlimab-rmbw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for nivolumab and relatlimab-rmbw Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for nivolumab and relatlimab-rmbw Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Nivolumab and Relatlimab-rmbw

Last updated: February 20, 2026

This analysis covers the current market landscape, growth drivers, competitive positioning, and revenue outlooks for the biologic drugs nivolumab and relatlimab-rmbw.

What Are Nivolumab and Relatlimab-rmbw?

Nivolumab (brand name Opdivo) is a PD-1 inhibitor developed by Bristol-Myers Squibb (BMS). It targets immune checkpoints to enhance the immune response against tumors. Approved for multiple indications, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and others, nivolumab's global sales exceeded $9 billion in 2022.

Relatlimab-rmbw (brand name Opdualag) is a combination of nivolumab and relatlimab, a LAG-3 inhibitor. Approved by the U.S. FDA in 2022 for unresectable or metastatic melanoma, it introduces a dual checkpoint blockade. It competes primarily with other combination immunotherapies.

What Is the Current Market Size?

Nivolumab Market

Indicator	2022 Data	Notes
Global sales	$9.2 billion	First approved in 2014; dominant among PD-1 inhibitors
Year-over-year growth	14%	Driven by expanding indications and geographic reach
Key indications	Melanoma, NSCLC, RCC, Hodgkin lymphoma, head and neck cancers	With approvals across solid tumors and hematologic cancers

Relatlimab-rmbw Market

Indicator	2022 Data	Notes
Estimated sales	~$300 million (initial launch)	Limited to melanoma; introduced late 2022
Market penetration	Early; primarily U.S.	Expanding into other markets within 2023
Competitive positioning	First-in-class LAG-3 inhibitor combination	Potential to disrupt existing melanoma treatments

What Are the Growth Drivers?

FDA and Global Approvals

Nivolumab's indications have extended to cancers such as small cell lung cancer, gastric cancer, and hepatocellular carcinoma. Its broad label and multiple accumulated approvals underpin sustained revenue growth.

Relatlimab gained accelerated approval in 2022, creating a new therapeutic option for melanoma. Its combination with nivolumab may improve efficacy and safety profiles over monotherapy.

Patent and Patent Expirations

Nivolumab's primary patents expire between 2028 and 2030, with patent extensions for certain formulations. Patent cliffs could reduce revenue unless companies develop next-generation or biosimilar versions or diversify indications.

Relatlimab’s patent status remains strong through 2030, providing market exclusivity.

Competitive Landscape

Nivolumab faces competition mainly from pembrolizumab (Keytruda) and ipilimumab (Yervoy). Market share is distributed based on approval breadth, efficacy, side effect profiles, and cost.

For relatlimab-rmbw, competitors include other combination regimens, such as nivolumab plus ipilimumab, and emerging therapies targeting LAG-3 or other immune checkpoints.

Pricing and Reimbursement Trends

Premium pricing persists, supported by demonstrated efficacy. Patients with private insurance, Medicare, and national health services cover the costs. Insurers favor combination therapies for their improved outcomes, enabling higher reimbursement levels.

R&D Pipeline and Future Indications

Nivolumab is under evaluation for over 70 ongoing trials spanning multiple tumor types. Its versatility supports pipeline expansion.

Relatlimab is also being tested with other immune checkpoint inhibitors, with potential to expand into lung, bladder, and other cancers.

What Are the Revenue Forecasts?

Nivolumab

Year	Projected Revenue	Notes
2023	~$10.5 billion	Growth driven by additional indications
2025	$12.5-$14 billion	Expected uptake of new indications, geographic expansion
2030	$15-$20 billion	Saturation of key markets, biosimilar entry unlikely until late 2030s

Relatlimab-rmbw

Year	Projected Revenue	Notes
2023	~$500 million	Launch expansion, limited to melanoma
2025	$1 billion	Broadened geographic reach, additional indications possible
2030	$2-$3 billion	Market adoption stabilizes, potential label expansions

What Are the Key Risks?

• Patent expiries threaten longer-term revenue stability.
• Regulatory delays or safety concerns could hinder adoption.
• Competitive pressure might erode market share.
• High acquisition costs for related biosimilars could alter market dynamics.
• Evolving reimbursement policies might impact profitability.

What Are the Financial Impacts for Stakeholders?

• Bristol-Myers Squibb maintains a dominant position in PD-1/PD-L1 space, with revenues from nivolumab constituting over 10% of total global sales.
• The success of relatlimab-rmbw could offset potential declines in nivolumab monotherapy sales.
• Early-stage pipeline candidates and new combo therapies could act as catalysts for future revenue growth.

Key Takeaways

• Nivolumab remains a leading immunotherapy with sustained high revenues; its growth persists due to broad approvals and expanding indications.
• Relatlimab-rmbw entered late 2022, with initial revenues modest but growing rapidly as market acceptance increases.
• Patent cliffs and intensifying competition pose risks, but pipeline expansion and label extensions can mitigate these pressures.
• Pricing strategies remain robust; reimbursement levels favor combination therapy adoption.
• Forecasts project continued revenue growth for both drugs, with nivolumab nearing peak sales in the mid-2020s and relatlimab-rmbw gaining market share through 2030.

FAQs

1. How does relatlimab-rmbw differ from existing PD-1/PD-L1 therapies?

Relatlimab-rmbw combines PD-1 and LAG-3 blockade, aiming to overcome resistance mechanisms. It is the first approved therapy targeting LAG-3 in combination with nivolumab for melanoma, potentially offering improved efficacy.

2. What are the main competitive threats to nivolumab?

Pembrolizumab (Keytruda) remains the primary competitor. Competition from biosimilars post-patent expiry and emerging immune checkpoint inhibitors targeting novel pathways further threaten market share.

3. When might biosimilars for nivolumab enter the market?

Patent expiry is expected around 2028-2030 in major markets. Biosimilar development is active, with regulatory approvals possible by late 2020s, potentially reducing prices.

4. What role do geographic markets play in revenue growth?

High growth in Asia-Pacific, especially China, supports revenues. Differing reimbursement policies and approvals in EU, US, and emerging markets influence sales trajectories.

5. How might regulatory developments impact the outlook?

Accelerated approvals, label expansions, or safety concerns could alter revenue potential. Changes in reimbursement policies, especially regarding combination therapies, can affect adoption.

---

References

1. Bristol-Myers Squibb. (2023). Opdivo (nivolumab) prescribing information. Retrieved from [BMS website].

2. U.S. Food and Drug Administration. (2022). FDA approves Opdualag for unresectable or metastatic melanoma. Accessed March 2023.

3. IQVIA. (2023). Global Oncology Market Data.

4. Datamonitor Healthcare. (2023). Biologics pipeline and patent expiry analysis.

5. Evaluate Pharma. (2023). World Preview 2023: Outlook to 2028.